JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwak, Y.-G.
Right arrow Articles by Tamkun, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwak, Y.-G.
Right arrow Articles by Tamkun, M. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 36, 25355-25361, September 3, 1999


Phosphorylation Is Required for Alteration of Kv1.5 K+ Channel Function by the Kvbeta 1.3 Subunit*

Yong-Geun Kwak, Ricardo A. Navarro-Polanco, Tammy Grobaski, Daniel J. GallagherDagger , and Michael M. Tamkun§

From the Departments of Physiology and Biochemistry and Molecular Biology, Colorado State University, Ft. Collins, Colorado 80523

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Kv1.5 K+ channel is functionally altered by coassembly with the Kvbeta 1.3 subunit, which induces fast inactivation and a hyperpolarizing shift in the activation curve. Here we examine kinase regulation of Kv1.5/Kvbeta 1.3 interaction after coexpression in human embryonic kidney 293 cells. The protein kinase C inhibitor calphostin C (3 µM) removed the fast inactivation (66 ± 1.9 versus 11 ± 0.25%, steady state/peak current) and the beta -induced hyperpolarizing voltage shift in the activation midpoint (V1/2) (-21.9 ± 1.4 versus -4.3 ± 2.0 mV). Calphostin C had no effect on Kv1.5 alone with respect to inactivation kinetics and V1/2. Okadaic acid, but not the inactive derivative, blunted both calphostin C effects (V1/2 = -17.6 ± 2.2 mV, 38 ± 1.8% inactivation), consistent with dephosphorylation being required for calphostin C action. Calphostin C also removed the fast inactivation (57 ± 2.6 versus 16 ± 0.6%) and the shift in V1/2 (-22.1 ± 1.4 versus -2.1 ± 2.0 mV) conferred onto Kv1.5 by the Kvbeta 1.2 subunit, which shares only C terminus sequence identity with Kvbeta 1.3. In contrast, modulation of Kv1.5 by the Kvbeta 2.1 subunit was unaffected by calphostin C. These data suggest that Kvbeta 1.2 and Kvbeta 1.3 subunit modification of Kv1.5 inactivation and voltage sensitivity require phosphorylation by protein kinase C or a related kinase.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Voltage-gated K+ channels represent a structurally and functionally diverse group of membrane proteins. These channels establish the resting membrane potential and modulate the frequency and duration of action potentials in nerve and muscle (1, 2). Multiple Shaker-like K+ channel alpha  and beta  subunit genes have been cloned from mammalian brain, heart, skeletal muscle, pancreas, and smooth muscle and functionally expressed in heterologous systems (2). The Kvbeta 1.1, 1.2, 1.3, and 3.1 subunits confer varying degrees of rapid inactivation onto members of the Kv1 family of delayed rectifiers (3-6). In addition, Kvbeta 1.2, 1.3, and 2.1 modify the voltage dependence of Kv1.5 channel opening by shifting the midpoint of activation 8-20 mV in the hyperpolarizing direction (4, 5, 7). Each Kvbeta subfamily is derived from a separate gene (Kvbeta 1, Kvbeta 2, and Kvbeta 3), whereas additional variability in the Kvbeta 1 subfamily results from alternative splicing in the N-terminal region, thus yielding the Kvbeta 1.1, 1.2, and 1.3 subunits (4). The variable N-terminal domains are responsible for the functional differences, whereas the conserved C-terminal domain most likely governs assembly with the alpha  subunit (8, 9).

Voltage-gated K+ channels are regulated via both serine/threonine and tyrosine phosphorylation. Kv1.1 and Kv1.2 currents are down-regulated by PKC1 activation (10, 11). Kv1.2 is down-regulated in part by a G-protein/PKC-dependent phosphorylation of tyrosine 132, whereas PKA phosphorylation of threonine 46 increases current (12, 13). Canine, but not human, Kv1.5 channel activity is decreased also by PKC activation in Xenopus oocytes (11), whereas the human Kv1.5 is down-regulated by tyrosine phosphorylation in HEK cells (14). Kv1.3 is down-regulated by both PKA and PKC in T-lymphocytes (15). K+ channel alpha /beta interactions are also influenced by phosphorylation. Lotan and co-workers (16) showed that PKA phosphorylation of serine 446 in the C terminus of Kv1.1 is necessary for the channel to be fully sensitive to fast inactivation conferred by the Kvbeta 1.1 subunit. Functional interactions between Kv1.5 and Kvbeta 1.3 are also regulated by PKA phosphorylation, with phosphorylation of serine 24 in the Kvbeta 1.3 subunit decreasing the beta -induced fast inactivation (17).

The Kvbeta 1.3 subunit converts Kv1.5 from a delayed rectifier with a modest degree of slow inactivation to a channel with both fast and slow components of inactivation (9). In addition, the activation curve is shifted in the hyperpolarizing direction. The present study was performed to determine whether PKC pathways modulate this particular alpha /beta interaction. We present data indicating that both the rapid inactivation and voltage sensitivity conferred onto Kv1.5 by Kvbeta 1.3 require PKC phosphorylation after heterologous expression in HEK 293 cells. Thus, the kinase systems active in heterologous systems must be taken into account when comparing currents in native cells to those generated from cloned channels. It remains to be determined whether this PKC requirement involves direct phosphorylation of either the alpha  or beta  subunits and/or other kinase systems.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Chemicals were purchased from Sigma unless indicated otherwise. Calphostin C, bisindolylmaleimide, phorbol 12-myristate 13-acetate, and okadaic acid were from Calbiochem. Tissue culture media and reagents, including LipofectAMINE, were obtained from Life Technologies, Inc. Calphostin C was activated by a 5-min exposure to light.

DNA Constructs-- Human Kv1.5 (-22-1894 nucleotides) and Kvbeta 1.3 (-53-1500 nucleotides) were inserted in tandem into the same vector with the Kv1.5 subunit placed 3' to the Kvbeta 1.3 subunit and behind an internal ribosome entry sequence (IRES), thus generating a dual cistronic mRNA. A modified pBKCMV vector (ATG-deleted pBK) that had the beta -galactosidase ATG at position 1415 removed (mutated to an NheI site) was used. The Kvbeta 1.3/IRES/Kv1.5 pBK vector was constructed as follows. A 590-base pair IRES (18) was subcloned into EcoRI/EcoRV-prepared pBSKS+. The above-mentioned K+ channel subunit fragments were blunted and subcloned into blunted XbaI and ClaI sites of the pBS polylinker that flanked the IRES. This construct was then digested with SalI, blunted, and digested with NotI to release the Kvbeta 1.3/IRES/Kv1.5 sequence. This fragment was then inserted into the NotI/SmaI-digested ATG-deleted pBKCMV.

For a limited number of experiments, Kvbeta 1.3 was co-expressed with a C-terminal deletion mutant of Kv1.5 (Delta C57hKv1.5), a 68-amino acid N-terminal deletion mutant of Kvbeta 1.3 (Delta N68Kvbeta 1.3) and wild type Kvbeta 1.2 or Kvbeta 2.1. The C-terminal deletion mutant of Kv1.5 (Delta C57hKv1.5) (19) was transferred from pGEM7 into wild-type pBK using EcoRI and HindIII and then transferred into the IRES construct using StuI. The Kvbeta 1.2 subunit NotI fragment (5) was blunted and subcloned into the SmaI site of the ATG-deleted pBK vector. The Delta N68Kvbeta 1.3 (9) was transferred from the Xenopus oocyte expression vector to ATG-deleted pBK by inserting a SalI-EcoRI fragment into these sites of the pBK polylinker. Wild type hKv1.5 in ATG-deleted pBK was made by removing an upstream NheI-SalI fragment containing the beta -galactosidase ATG from the previously described Kv1.5/pBK construct (7). The wild type Kvbeta 2.1 in wild type pBK has been previously described (7).

Construction of the Kvbeta 1.3-Kv1.5 tandem was as follows. The single SphI site at nucleotide 316 of the Kvbeta 1.3 sequence was removed, and the stop codon was changed to an SphI site using the Quick Change site-directed mutagenesis kit from Stratagene. This fragment was then ligated in-frame to the SphI site just 5' to the Kv1.5 start codon as described previously (9).

Transfection of HEK 293 Cells-- Recently thawed HEK 293 cells (ATCC#1573-CRL) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% horse serum. Cells were transiently transfected by the LipofectAMINE method according to supplier's directions. Soluble GFP was coexpressed with the channel subunits to identify cells for voltage clamp analysis as described previously (7). The transient transfections used 2.5 ng of hKv1.5/pBK, 4 µg of Kvbeta 1.3/IRES/hKv1.5 pBK and Kvbeta 1.3pBK, 1.5 µg of Kvbeta 1.2/pBK, 4.0 µg of Kvbeta 2.1/pBK, 4.0 µg of Delta N68Kvbeta 1.3pBK, 4.0 µg of Kvbeta 1.3/IRES/Delta C57hKv1.5, 0.4 µg of Kvbeta 1.3-hKv1.5 tandem, and 0.5 µg of GFP/pCI (7) mixed with 25 µl of LipofectAMINE reagent. The lipofection mixture was applied overnight, after which the standard culture medium was restored. After 24-48 h the cells were removed from the dish using brief trypsinization, washed twice with maintenance medium, and stored at room temperature for recording within the next 12 h. Three µM calphostin C was added to cells and incubated for 0.5-2 h at room temperature before seal formation and voltage clamp. Five µM bisindolylmaleimide was added during an overnight incubation at 37 °C. When used, okadaic acid (3 µM) was added 30 min before calphostin C.

Electrical Recording-- Transfection efficiency averaged 30-40% based on green protein fluorescence, and >90% of green cells expressed current showing a complete Kvbeta 1.3 effect. Recordings were made with an Axopatch-200B patch clamp amplifier (Axon Instruments, Foster City, CA) using the whole cell configuration of the patch clamp technique. Currents were recorded at room temperature (21-23 °C) and were sampled at 1-10 kHz after anti-alias filtering at 0.5 to 5 kHz. Data acquisition and command potentials were controlled by pClamp software (Axon Instruments, Foster City, CA). To ensure voltage clamp quality, electrode resistance was kept below 3 megaohms. Junction potentials were zeroed with the electrode in the standard bath solution. Gigaohm seal formation was achieved by suction, and after establishing the whole cell configuration, the capacitive transients elicited by symmetrical 10-mV voltage clamp steps from -80 mV were recorded at 50 kHz for calculation of cell capacitance.

Solutions-- The intracellular pipette-filling solution contained 100 mM KCl, 10 mM HEPES, 5 mM K4BAPTA, 5 mM K2ATP, and 1 mM MgCl2 and was adjusted to pH 7.2 with KOH, yielding a final intracellular K+ concentration of ~145 mM. The bath solution contained 130 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose and was adjusted to pH 7.35 with NaOH.

Pulse Protocols and Analysis-- The holding potential was -80 mV, and the cycle time for the protocols was 20 s. The standard protocol to obtain current-voltage relationships and activation curves consisted of 250-ms pulses that were imposed in 10-mV increments between -80 and +60 mV. The steady state currents were obtained at the end of the 250-ms depolarizations to +60 mV. Percent inactivation was calculated as 1 - (steady state current/peak current amplitude). Deactivating tail currents were recorded at -30 or -50 mV. The activation curve was obtained from the ratio of tail current amplitudes measured immediately after decay of the capacitive transients. The voltage dependence of channel opening (activation curve) was fitted with a Boltzmann equation, y = 1/1(1 + exp(-(E - Eh)/k)), in which k represents the slope factor, and Eh represents the voltage at which 50% of the channels are open.

The results are expressed as the mean ± S.E. The Student's t test was used to calculate the statistical significance of the differences between two populations. Values of p < 0.05 were considered to indicate statistical significance.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Kvbeta 1.3 subunit alters Kv1.5 function by 1) inducing a rapid, but incomplete, voltage-dependent inactivation, 2) a hyperpolarizing shift in the midpoint of activation, 3) a slowing of deactivation, and 4) enhanced slow inactivation (4, 9). Our previous work has shown that the fast inactivation conferred by Kvbeta 1.3 onto Kv1.5 is reduced specifically by PKA phosphorylation of serine 24 in the beta  subunit (17). The present study was performed to determine whether PKC pathways also regulated this alpha /beta interaction. Since PKC inhibitors such as calphostin C directly inhibit L-type Ca2+ channels (20), we first incubated Kv1.5-transfected HEK 293 cells with a variety of PKC inhibitors to test for direct effects on the Kv1.5 channel. We found that the PKC inhibitor chelerythrine was a potent open channel blocker with a K0.5 value in the low micromolar range when applied to the bath solution (data not shown). This block was apparent within minutes of application to the bath. Given the charge and hydrophobicity of this compound, such open channel block was not surprising because it is structurally similar to well characterized open channel blockers such as quinidine (21). However, 3 µM calphostin C, which is structurally distinct from chelerythrine, showed no open channel block of the Kv1.5 current (compare panels A and B, Fig. 1), although this agent did slow the rate of both activation and deactivation as well as decrease the slope of the activation curve (panels B, C, and D, respectively). Since direct addition of calphostin C to the bath solution produced these minor effects within 5 min, they most likely represent a direct effect on the channel as opposed to involving kinase pathways.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of calphostin C on Kv1.5 current. Kv1.5 currents were recorded from transiently transfected HEK 293 cells under control conditions and after a 2-h incubation with 3 µM calphostin C (panels A and B, respectively). Panel C shows the effect of calphostin C treatment on normalized Kv1.5 tail currents recorded at -30 mV after a 250-ms depolarization to +60 mV. The activation curve, as determined from peak tail currents at -30 mV, is illustrated in panel D. Calphostin C treatment and voltage clamp recordings were performed as described under "Experimental Procedures."

The effects of calphostin C on the Kvbeta 1.3-induced modification of Kv1.5 current were examined next. As shown in Fig. 2, panels A and B, the Kvbeta 1.3 subunit induced its characteristic fast inactivation upon Kv1.5. Preincubation with calphostin C (3 µM) for 2 h essentially removed the beta -induced fast inactivation as shown in panel C. This effect of calphostin C was not observed when the agent was added directly to the bath after seal formation and incubated for 30 min or less. Only when the cells were preincubated with calphostin C for 1-2 h before seal formation or once, when the seal was maintained for more than 30 min after calphostin C addition, was loss of inactivation observed. The data presented in panel D show that 3 µM okadaic acid, an inhibitor of protein phosphatases 1 and 2A (22), attenuated the calphostin C effect, as predicted if protein dephosphorylation is required to remove the beta -induced inactivation. The data summarized in panel E illustrate that calphostin C also affected the beta -induced hyperpolarizing shift in the activation curve. Calphostin C completely removed the beta -induced voltage shift, whereas okadaic acid prevented this removal. Okadaic acid alone had no effect on the Kv1.5/Kvbeta 1.3 current or the current induced by Kv1.5 alone (data not shown). Although calphostin C removed the beta -induced inactivation and the hyperpolarizing shift in the activation curve, it did not negate the beta -induced slowing of deactivation but rather slowed it further (tau  = 34.6 versus 41.5 ms, without and with calphostin C treatment, respectively). This calphostin C-induced slowing of deactivation agrees with the data of Fig. 1 indicating calphostin C directly slows Kv1.5 deactivation. The PKC inhibitor bisindolylmaleimide also inhibited beta -induced inactivation as shown in panel E. Phorbol 12-myristate 13-acetate (10 µM, added directly to the bath or preincubated with the cells for either 2 or 12 h) had no effect on the Kv1.5/Kvbeta 1.3 current (data not shown).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of calphostin C on Kv1.5/Kvbeta 1.3 current. Panels A-C show outward currents recorded from HEK 293 cells transfected with Kv1.5 alone, Kv1.5 plus Kvbeta 1.3, and Kv1.5 plus Kvbeta 1.3 followed by treatment with 3 µM calphostin C for 2 h at room temperature before seal formation and voltage clamp, respectively. Panel D shows currents from Kv1.5 plus Kvbeta 1.3-transfected cells that were incubated with 3 µM okadaic acid for 30 min before a 2-h incubation with both 3 µM okadaic acid and 3 µM calphostin C. The activation curves, as obtained from peak tail current amplitude, for either Kv1.5 alone, Kv1.5 plus Kvbeta 1.3, Kv1.5 plus Kvbeta 1.3 with phorbol 12-myristate 13-acetate (PMA), Kv1.5 plus Kvbeta 1.3 with calphostin C, and Kv1.5 plus Kvbeta 1.3 with calphostin C and okadaic acid are shown in panel E. Panel F shows outward currents recorded from cells transfected with Kv1.5 plus Kvbeta 1.3 after overnight treatment with 5 µM bisindolylmaleimide.

Deletion of the N-terminal 68 amino acids of Kvbeta 1.3 removes the fast inactivation but not the beta -induced shift in activation midpoint (9). To determine whether these N-terminal amino acids, including a consensus sites for PKC phosphorylation at serine 34, are required for the calphostin C effects, we examined the effect of calphostin C on this truncated beta  subunit coexpressed with Kv1.5. As shown in Fig. 3, panels A and B, no fast inactivation was observed both in the absence and presence of calphostin C. However, the hyperpolarizing shift in the activation was still present, and calphostin C treatment returned the activation midpoint to that observed in the absence of a beta  subunit (panel C). These data indicate that the first 68 amino acids of Kvbeta 1.3, although being essential for the beta -induced fast inactivation, are not required for the beta  subunit to render alpha /beta -derived current PKC-sensitive.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of calphostin C on Kv1.5 and Kvbeta 1.3 deletion mutants. The top row, panels A-C, illustrate the effect of calphostin C on currents produced by expression of Kv1.5 with an N-terminal deletion mutant of Kvbeta 1.3 that lacked the first 68 amino acids. Control currents and those recorded after a 2-h incubation with 3 µM calphostin C are shown in panels A and B, respectively. The activation curves generated under these two conditions are shown in panel C as is the activation curve for Kv1.5 in the absence of any beta  subunit. The bottom row, panels D-F, show the effect of calphostin C on the currents produced by expression of Kvbeta 1.3 with a C-terminal truncated mutant of Kv1.5 that lacked the final 57 amino acids. Again, control currents and those recorded after a 2-h incubation with 3 µM calphostin C are shown in panels D and E, respectively. The activation curves generated under these two conditions are shown in panel F.

The fast inactivation conferred onto Kv1.1 by the Kvbeta 1.1 subunit requires phosphorylation at a PKA site (serine 446) in the alpha  subunit C terminus (23). To determine whether the two PKA and two PKC sites present in the C terminus of Kv1.5 were involved in the PKC regulation of Kv1.5/Kvbeta 1.3 interaction, we studied a C-terminal truncation of Kv1.5 (Delta C57Kv1.5) that is missing these potential phosphorylation sites. As illustrated in Fig. 3D, the Kvbeta 1.3 subunit induced its characteristic fast inactivation upon this truncated channel, and calphostin C continued to negate the beta -induced inactivation and voltage shift (panels E and F, respectively). Thus, the phosphorylation sites in the Kv1.5 C terminus play no role in either the beta -induced inactivation or voltage shift or the PKC regulation of these processes.

The Kvbeta 1 isoforms are produced by alternative splicing of the N terminus. Thus, the N-terminal amino acids differ completely between isoforms, whereas the C-terminal 329 amino acids are identical (4). Fig. 4, panels A-C, examine the effect of calphostin C treatment on the current generated by Kv1.5 and Kvbeta 1.2 co-expression. As shown in panel A, Kvbeta 1.2 confers a rapid inactivation onto Kv1.5 and, as with Kvbeta 1.3, Kvbeta 1.2 induces a hyperpolarizing shift in the activation curve. Panel B shows that calphostin C reduces the beta -induced inactivation, and panel C shows that calphostin C returned the activation curve to the position observed in the absence of any beta  subunit. Therefore, the mechanism of calphostin C action is shared between Kvbeta 1.3 and beta 1.2.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of calphostin C on Kvbeta 1.2- and Kvbeta 2.1-modulated Kv1.5 current. The top row, panels A-C, illustrate the effect of calphostin C on currents produced by expression of Kv1.5 with Kvbeta 1.2, an N-terminal splice variant of Kvbeta 1.3. Control currents and those recorded after a 2-h incubation with 3 µM calphostin C are shown in panels A and B, respectively. The activation curves generated under these two conditions are shown in panel C. The bottom row, panels D-F, show the effect of calphostin C on the currents produced by expression of Kv1.5 with Kvbeta 2.1. Control currents and those recorded after a 2-h incubation with 3 µM calphostin C are shown in panels D and E, with the activation curves generated under these two conditions shown in panel F.

The Kvbeta 2.1 protein is derived from a different gene and has a unique N terminus and only 85% identity in the C-terminal region as compared with the Kvbeta 1 family (4). This subunit does not confer fast inactivation onto the Kv1.5 channel, but it does produce a hyperpolarizing shift in the activation curve (7). Panels D and E in Fig. 4 indicate that calphostin C had no effect on Kvbeta 2.1 action during the 250-ms depolarizing stimulus to +60 mV. Importantly, panel F shows that calphostin C failed to shift the activation curve toward that observed in the absence of any beta  subunit (V1/2 = 2.7 ± 1.0 mV). Thus, Kvbeta 2.1 subunit action, which is primarily a 10-12-mV hyperpolarizing shift in the activation curve, is resistant to calphostin C treatment.

One possible interpretation of the results presented above is that calphostin C either inhibited alpha /beta assembly or induced dissociation of the alpha /beta complexes already on the cell surface. However, it is unlikely that calphostin C was affecting subunit assembly during de novo synthesis, since as little as 30 min of calphostin C treatment was required to remove the inactivation and voltage shift. This amount of time is insufficient to replace all cell surface protein with newly synthesized material, especially at room temperature, because the turnover rate for the Kv1.5 channel is approximately 4 h at 37 °C (24). However, since subunit dissociation remained a possibility, we constructed a tandem alpha /beta complex in which the C terminus of Kvbeta 1.3 was fused with the N terminus of Kv1.5. As shown in Fig. 5, this tandem construct retained wild type alpha /beta activity in terms of fast inactivation and the activation midpoint (69.48 ± 2.15% inactivation at +60 mV and 250 ms, V1/2 = -21.47 ± 4.19 mV, n = 12) (panels A and B, respectively). Fig. 5, C and D show that this tandem also had the typical response to calphostin C in that both the fast inactivation and hyperpolarizing voltage shift were removed (22.93 ± 3.07% inactivation at +60 mV and 250 ms, activation midpoint = -9.82 ± 8.64 mV, n = 6). Thus, PKC activity is unlikely to be modulating subunit assembly in this expression system.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of calphostin C on the Kvbeta 1.3-Kv1.5 tandem. This tandem was constructed as described under "Experimental Procedures." Control currents and those obtained after a 30-min incubation with 1 µM calphostin C are shown in panels A and C, respectively. Currents were recorded in response to 10-mV depolarizations from a holding potential of -80 mV. Panels B and D contain activation curves derived from the peak tail currents in panels A and C, respectively.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Kvbeta 1.3 subunit alters the function of Kv1.5 by mainly conferring a rapid but incomplete inactivation and a hyperpolarizing shift in the activation curve. Although the PKC inhibitor calphostin C had only minor effects on the current produced by Kv1.5 alone, this agent dramatically altered the current observed in the presence of the Kvbeta 1.3 subunit. The fast inactivation was removed by calphostin C treatment as was the hyperpolarizing shift in the activation curve (Table I). There was also a change in the slope of the activation curve in the presence of calphostin C. However, this slope change is likely to be related to removal of the beta -induced inactivation. It is inherently difficult to compare activation curves between Kv1.5 alone and Kv1.5 in the presence of an inactivation-inducing beta  subunit, for the beta -induced inactivation probably affects the peak tail currents as previously discussed (9) and, thus, artificially alters any activation curve generated from peak tail currents. Still, Kvbeta 1.3 does enhance the voltage sensitivity independent of the induced inactivation, since a hyperpolarizing voltage shift occurs with the Kvbeta 1.3 N-terminal truncation, and calphostin C treatment returns this activation curve to that observed in the absence of any beta  subunit (Fig. 3C). Also arguing against alpha /beta dissociation is the fact that forced assembly via use of the alpha /beta tandem shows the expected calphostin C response. However, it remains possible that calphostin C does induce dissociation with separate proteins, but dissociation is not observed when the two subunits are physically linked, since reassociation is highly favored under these conditions.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summary of the calphostin C-induced effects on the channel kinetics
Parameters are determined as described in text. PMA, phorbol 12-myristate 13-acetate.

Care must be exercised to avoid studying a direct action of calphostin C on ion channel function as opposed to modulating kinase pathways. However, calphostin C had little effect on the current produced by Kv1.5 alone. If calphostin C was having a direct effect on the Kv1.5/Kvbeta 1.3 complex, there would be no preincubation requirement, and okadaic acid would not be expected to antagonize its action. Furthermore, an inactive analog of okadaic acid, okadaic acid tetraacetate (25), did not antagonize calphostin C action (data not shown). Bisindolylmaleimide, another PKC inhibitor, also prevented the Kvbeta 1.3-induced inactivation. However, an effect of this inhibitor was observed in only 5 of 10 experiments, and the activation curve was not shifted (data not shown). These data may suggest that complete PKC block is required to shift the activation curve, whereas only a partial block is needed to inhibit inactivation. Alternatively, different PKC isoforms could be involved that show differential inhibitor sensitivity, as has been previously described by other investigators in other systems (23, 26, 27). Inhibitor peptides that block Ca2+-dependent PKC isoforms did not alter Kv1.5/Kvbeta 1.3 interaction (data not shown). This finding agrees with the fact that the BAPTA present in the intracellular solution does not alter Kv1.5/Kvbeta 1.3 current, which is expected if Ca2+-insensitive PKC isoforms are involved in regulating subunit interaction.

Two major questions raised by the data presented here are, 1) is direct PKC phosphorylation of the Kv1.5/Kvbeta 1.3 complex occurring, and 2) if direct phosphorylation is occurring, which sites are phosphorylated? Our working hypothesis is that PKC phosphorylation of either the alpha  or beta  subunit is required to render the Kv1.5 channel sensitive to the beta -induced inactivation and voltage shift. Multiple PKC isozymes have been reported in HEK 293 cells (28) as well as PKC activity in the absence of PKC activators (29, 30). Therefore, it is not surprising that aspects of this signaling system are constitutively active and that removal of this phosphorylation requires the use of PKC inhibitors. The time required to observe the calphostin C effects, 1 h on average, is consistent with this proposed mechanism; for time is required for the calphostin C to enter the cell and inhibit the required PKC isoform. Additional time is required for dephosphorylation via protein phosphatases. Also supporting this scenario is the finding that okadaic acid, an inhibitor of protein phosphatases 1 and 2A (22) that alone has no effect on Kv1.5/Kvbeta 1.3 current (data not shown), inhibits the calphostin C effects on both the inactivation and hyperpolarizing voltage shift. Kv channel alpha  and beta  subunits are basally phosphorylated, and these phosphorylation events probably occur early in biosynthesis (31-33). Hence, it is likely that the channel complex is stably phosphorylated on PKC sites and that this phosphorylation is required for complete alpha /beta functional interaction. Where such a single phosphorylation site may exist is at present unknown. Many potential PKC consensus sequences exist in both the Kv1.5 and Kvbeta 1.3 proteins (34). Since the Kvbeta 1.2 subunit, but not the Kvbeta 2.1 subunit, is sensitive to calphostin C (Fig. 4), we examined these C-terminal sequences for differences in possible PKC phosphorylation sites. Serine 314 in Kvbeta 1.3 could be phosphorylated by PKC, and the corresponding site is absent in Kvbeta 2.1. However, mutation of this serine in Kvbeta 1.3 to alanine had no effect on the control currents or the calphostin C response (data not shown). Either other sites are involved or there is no direct PKC phosphorylation of the alpha /beta complex. For example, PKC can modulate tyrosine kinase phosphorylation of Kv1.5 expressed without a beta  subunit (12).

In summary, there is no reason at present to believe we are dealing with only a single PKC site on either the Kv1.5 or Kvbeta 1.3 proteins that must be phosphorylated to allow the beta -induced inactivation and voltage shift. Additional experiments are required to define the mechanism by which calphostin C removes the beta -induced inactivation and hyperpolarizing voltage shift in the Kv1.5/Kvbeta 1.3 complex. Since the bisindolylmaleimide does not fully mimic the calphostin C and all known PKC isoforms that are sensitive to both agents, it is possible that a kinase other than PKC is involved. Whatever the exact mechanism, the data presented here introduce additional complexity to the topic of beta  subunit modulation of Kv channel function.

    ACKNOWLEDGEMENTS

We thank Shelly Sullivan for technical assistance and Drs. Jeff Martens and JoAnne Hulme for review of the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant HL49330 (to M. M. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Dept. of Pharmacology, SJ-30 University of Washington School of Medicine, Seattle, WA 98195.

§ To whom correspondence should be addressed: Dept. of Physiology, Colorado State University, Ft. Collins, CO 80523. Tel.: 970-491-3484; Fax: 970-491-7569; tamkunmm@lamar.colostate.edu.

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; PKA, protein kinase A; HEK 293, human embryonic kidney cells; IRES, internal ribosome entry sequence.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Chandy, K. G., and Gutman, G. A. (1995) in Handbook of Receptors and Channels: Ligand- and Voltage-gated Ion Channels (North, R. A., ed) , pp. 1-71, CRC Press, LLC, Boca Raton, FL
2. Deal, K. K., England, S. K., and Tamkun, M. M. (1996) Physiol. Rev. 76, 49-67[Abstract/Free Full Text]
3. Heinemann, S. H., Rettig, J., Wunder, F., and Pongs, O. (1995) FEBS Lett. 377, 383-389[CrossRef][Medline] [Order article via Infotrieve]
4. England, S. K., Uebele, V. N., Kodali, J., Bennett, P. B., and Tamkun, M. M. (1995) J. Biol. Chem. 270, 28531-28534[Abstract/Free Full Text]
5. England, S. K., Uebele, V. N., Shear, H., Kodali, J., Bennett, P. B., and Tamkun, M. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6309-6313[Abstract/Free Full Text]
6. Rettig, J., Heinemann, S. H., Wunder, F., Lorra, C., Parcej, D. N., Dolly, J. O., and Pongs, O. (1994) Nature 369, 289-294[CrossRef][Medline] [Order article via Infotrieve]
7. Uebele, V. N., England, S. K., Chaudhary, A., Tamkun, M. M., and Snyders, D. J. (1996) J. Biol. Chem. 271, 2406-2412[Abstract/Free Full Text]
8. Accili, E. A., Kiehn, J., Yang, Q., Wang, Z., Brown, A. M., and Wible, B. A. (1997) J. Biol. Chem. 272, 25824-25831[Abstract/Free Full Text]
9. Uebele, V. N., England, S. K., Gallagher, D. J., Snyders, D. J., Bennett, P. B., and Tamkun, M. M. (1998) Am. J. Physiol. 43, C1485-C1495
10. Peretz, T., Levin, G., Moran, O., Thornhill, W. B., Chikvashvili, D., and Lotan, I. (1996) FEBS Lett. 381, 71-76[CrossRef][Medline] [Order article via Infotrieve]
11. Vogalis, F., Ward, M., and Horowitz, B. (1995) Mol. Pharmacol. 48, 1015-1023[Abstract]
12. Huang, X.-Y., Morielli, A. D., and Peralta, E. G. (1993) Cell 75, 1145-1156[CrossRef][Medline] [Order article via Infotrieve]
13. Huang, X.-Y., Morielli, A. D., and Peralta, E. G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 624-628[Abstract/Free Full Text]
14. Holmes, T. C., Fadool, D. A., Ren, R. B., and Levitan, I. B. (1996) Science 274, 2089-2091[Abstract/Free Full Text]
15. Payet, M. D., and Dupuis, G. (1992) J. Biol. Chem. 267, 18270-18283[Abstract/Free Full Text]
16. Levin, G., Chikvashvili, D., Singer-Lahat, D., Peretz, T., Thornhill, W. B., and Lotan, I. (1996) J. Biol. Chem. 271, 29321-29328[Abstract/Free Full Text]
17. Kwak, Y. G., Hu, N. N., Wei, J., George, A. L., Grobaski, T. D., Tamkun, M. M., and Murray, K. T. (1999) J. Biol. Chem. 274, 13928-13932[Abstract/Free Full Text]
18. Ghattas, I. R., Sanes, J. R., and Majors, J. E. (1991) Mol. Cell. Biol. 11, 5848-5859[Abstract/Free Full Text]
19. Uebele, V. N., Yeola, S. W., Snyders, D. J., and Tamkun, M. M. (1994) FEBS Lett. 340, 104-108[CrossRef][Medline] [Order article via Infotrieve]
20. Hartzell, H. C., and Rinderknecht, A. (1996) Am. J. Physiol. 270, C1293-C1299[Abstract/Free Full Text]
21. Snyders, D. J., Knoth, K. M., Roberds, S. L., and Tamkun, M. M. (1992) Mol. Pharmacol. 41, 332-339
22. Sheppeck, J. E. N., Gauss, C. M., and Chamberlin, A. R. (1997) Bioorg. Med. Chem. Lett. 5, 1739-1750
23. Levy, M., Jing, J., Chikvashvili, D., Thornhill, W. B., and Lotan, I. (1998) J Biol Chem 273, 6495-6502[Abstract/Free Full Text]
24. Takimoto, K., Fomina, A. F., Gealy, R., Trimmer, J. S., and Levitan, E. S. (1993) Neuron 11, 359-369[CrossRef][Medline] [Order article via Infotrieve]
25. Swain, J. E., Robitaille, R., Dass, G. R., and Charlton, M. P. (1991) J. Neurobiol. 22, 855-864[CrossRef][Medline] [Order article via Infotrieve]
26. Watts, S. W., Cox, D. A., Johnson, B. G., Schoepp, D. D., and Cohen, M. L. (1994) J. Pharmacol. Exp. Ther. 271, 832-844[Abstract/Free Full Text]
27. Jirousek, M. R., Gillig, J. R., Gonzalez, C. M., Heath, W. F., McDonald, J. H. R., Neel, D. A., Rito, C. J., Singh, U., Stramm, L. E., Melikian-Badalian, A., Baevsky, M., Ballas, L. M., Hall, S. E., Winneroski, L. L., and Faul, M. M. (1996) J. Med. Chem. 39, 2664-2671[CrossRef][Medline] [Order article via Infotrieve]
28. Martel, J., Dupuis, G., Deschenes, P., and Payet, M. D. (1998) J. Membr. Biol. 161, 183-196[CrossRef][Medline] [Order article via Infotrieve]
29. Innamorati, G., Sadeghi, H., and Birnbaumer, M. (1998) J. Biol. Chem. 273, 7155-7161[Abstract/Free Full Text]
30. Eilers, H., Schaeffer, E., Bickler, P. E., and Forsayeth, J. R. (1997) Mol. Pharmacol. 52, 1105-1112[Abstract/Free Full Text]
31. Deal, K. K., Lovinger, D. M., and Tamkun, M. M. (1994) J. Neurosci. 14, 1666-1676[Abstract]
32. Shi, G., Kleinklaus, A. K., Marrion, N. V., and Trimmer, J. S. (1994) J. Biol. Chem. 269, 23204-23211[Abstract/Free Full Text]
33. Cai, Y.-C., and Douglass, J. (1993) J. Biol. Chem. 268, 23720-23727[Abstract/Free Full Text]
34. Hofmann, J. (1997) FASEB J. 11, 649-69[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
D. Dobrev and E. Wettwer
Four and a half LIM protein 1: a novel chaperone for atrium-specific Kv1.5 channels with a potential role in atrial arrhythmogenesis
Cardiovasc Res, June 1, 2008; 78(3): 411 - 412.
[Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. V. Remillard, D. D. Tigno, O. Platoshyn, E. D. Burg, E. E. Brevnova, D. Conger, A. Nicholson, B. K. Rana, R. N. Channick, L. J. Rubin, et al.
Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension
Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1837 - C1853.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. D. Benson, Q.-J. Li, K. Kieckhafer, D. Dudek, M. R. Whorton, R. K. Sunahara, J. A. Iniguez-Lluhi, and J. R. Martens
SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5
PNAS, February 6, 2007; 104(6): 1805 - 1810.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
M. Saito, Y. Murai, H. Sato, Y.-C. Bae, T. Akaike, M. Takada, and Y. Kang
Two Opposing Roles of 4-AP-Sensitive K+ Current in Initiation and Invasion of Spikes in Rat Mesencephalic Trigeminal Neurons
J Neurophysiol, October 1, 2006; 96(4): 1887 - 1901.
[Abstract] [Full Text] [PDF]


Home page
NeuroscientistHome page
Y. Li, S. Y. Um, and T. V. Mcdonald
Voltage-Gated Potassium Channels: Regulation by Accessory Subunits
Neuroscientist, June 1, 2006; 12(3): 199 - 210.
[Abstract] [PDF]


Home page
J. Immunol.Home page
R. Vicente, A. Escalada, C. Soler, M. Grande, A. Celada, M. M. Tamkun, C. Solsona, and A. Felipe
Pattern of Kv{beta} Subunit Expression in Macrophages Depends upon Proliferation and the Mode of Activation
J. Immunol., April 15, 2005; 174(8): 4736 - 4744.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. Gonzalez, R. Navarro-Polanco, C. Arias, R. Caballero, I. Moreno, E. Delpon, J. Tamargo, M. M. Tamkun, and C. Valenzuela
Assembly with the Kvbeta 1.3 Subunit Modulates Drug Block of hKv1.5 Channels
Mol. Pharmacol., December 1, 2002; 62(6): 1456 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Krick, O. Platoshyn, S. S. McDaniel, L. J. Rubin, and J. X.-J. Yuan
Augmented K+ currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis
Am J Physiol Lung Cell Mol Physiol, October 1, 2001; 281(4): L887 - L894.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Ma, J. Pluznick, P. Kudlacek, and S. C. Sansom
Protein Kinase C Activates Store-operated Ca2+ Channels in Human Glomerular Mesangial Cells
J. Biol. Chem., July 6, 2001; 276(28): 25759 - 25765.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow